FULGENT GENETICS, INC. Payments to Acquire Equity Method Investments
FULGENT GENETICS, INC. (FLGT) reported Payments to Acquire Equity Method Investments of $3.97 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireEquityMethodInvestments · last filed 2023-02-28
- FULGENT GENETICS, INC. payments to acquire equity method investments for the quarter ending 2020-12-31 was $0.00.
- FULGENT GENETICS, INC. payments to acquire equity method investments for the quarter ending 2018-12-31 was $0.00.
- FULGENT GENETICS, INC. payments to acquire equity method investments for the quarter ending 2018-09-30 was $0.00.
- FULGENT GENETICS, INC. payments to acquire equity method investments for the quarter ending 2017-12-31 was $0.00.
- FULGENT GENETICS, INC. payments to acquire equity method investments for fiscal 2020 was $3.97M, a 2798.54% increase from fiscal 2019.
- FULGENT GENETICS, INC. payments to acquire equity method investments for fiscal 2019 was $137.00K, a 73.14% decline from fiscal 2018.
- FULGENT GENETICS, INC. payments to acquire equity method investments for fiscal 2018 was $510.00K, a 79.28% decline from fiscal 2017.
- FULGENT GENETICS, INC. payments to acquire equity method investments for fiscal 2017 was $2.46M.
| Period end | Payments to Acquire Equity Method Investments 3 month | Payments to Acquire Equity Method Investments 6 month | Payments to Acquire Equity Method Investments 9 month | Payments to Acquire Equity Method Investments 9 month as first filed | Payments to Acquire Equity Method Investments 12 month | Payments to Acquire Equity Method Investments 12 month as first filed |
|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $3.97M 10-K · filed 2023-02-28 | $2.59M 10-K · filed 2021-03-08 | |||
| 2020-09-30 | $3.97M 10-Q · filed 2021-11-09 | $2.59M 10-Q · filed 2020-11-09 | ||||
| 2019-12-31 | $137.00K 10-K · filed 2022-02-28 | |||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $0.00 derived: sum of 2 quarters · filed 2020-03-13 | $510.00K 10-K · filed 2020-03-13 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $510.00K 10-Q · filed 2019-11-08 | ||||
| 2018-06-30 | $510.00K 10-Q · filed 2019-08-12 | |||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $2.46M 10-K · filed 2019-03-22 | ||||
| 2017-09-30 | $2.46M 10-Q · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |